Molecular Testing to Direct Extent of Initial Thyroid Surgery
Primary Purpose
Thyroid Cancer
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Thyroid lobectomy
Total thyroidectomy with CCND
Sponsored by
About this trial
This is an interventional treatment trial for Thyroid Cancer focused on measuring thyroid cancer, thyroid nodule, thyroidectomy, personalized medicine
Eligibility Criteria
Inclusion Criteria:
- Thyroid nodule is >1.5 cm
- Preoperative FNA biopsy that is positive for papillary thyroid cancer or suspicious for papillary thyroid cancer
Exclusion Criteria:
- Prior thyroid/parathyroid surgery
- Clinical indications for total thyroidectomy including hypothyroidism, history of head or neck radiation when <18 years old
- Recurrent laryngeal nerve dysfunction
- Diagnosis of concurrent primary hyperparathyroidism
Sites / Locations
- University of Pittsburgh
- Medical College of Wisconsin
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
Low Risk
High Risk
Arm Description
Molecular testing and ultrasound features will be used to predict if thyroid cancer is low risk. Intervention will be to perform thyroid lobectomy.
Molecular testing and ultrasound features will be used to predict if thyroid cancer is high risk. Intervention will be to perform more aggressive surgery to include total thyroidectomy with CCND.
Outcomes
Primary Outcome Measures
Number of patients who require completion thyroidectomy for aggressive histology features
Histology characteristics of tumor will be assessed including type of cancer, extrathyroidal extension, lymph node metastasis, and margin status to assess if completion thyroidectomy is needed per the 2015 ATA guidelines
Secondary Outcome Measures
Number of patients who had central compartment neck dissection but no lymph node metastasis were identified
Number of patients with operative complications
incidence of permanent nerve injury, hypocalcemia, readmission
Recurrence
QOL metric - FACT-G cumulative score preop, postop, and at followup
QOL metric - QOL-Thyroid cumulative score preop, postop, and at followup
QOL metric - SF36 cumulative score preop, postop, and at followup
Full Information
NCT ID
NCT02947035
First Posted
October 20, 2016
Last Updated
July 12, 2023
Sponsor
University of Pittsburgh
1. Study Identification
Unique Protocol Identification Number
NCT02947035
Brief Title
Molecular Testing to Direct Extent of Initial Thyroid Surgery
Official Title
Molecular Testing to Direct Extent of Initial Thyroid Surgery
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Completed
Study Start Date
February 1, 2017 (Actual)
Primary Completion Date
June 1, 2023 (Actual)
Study Completion Date
June 1, 2023 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Pittsburgh
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The research study consists of the participant agreeing to 1) the use of preoperative molecular testing (ThyroSeq) to guide extent of initial surgery and 2) the prospective collection of medical record data related to treatment of thyroid cancer.
Detailed Description
The aim of the proposed pilot study is to use a clinical algorithm that incorporates molecular, clinical and radiographic factors to inform surgical management. This study is the first to propose molecular-directed surgical management for this commonly diagnosed cancer.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Thyroid Cancer
Keywords
thyroid cancer, thyroid nodule, thyroidectomy, personalized medicine
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
100 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Low Risk
Arm Type
Experimental
Arm Description
Molecular testing and ultrasound features will be used to predict if thyroid cancer is low risk. Intervention will be to perform thyroid lobectomy.
Arm Title
High Risk
Arm Type
Experimental
Arm Description
Molecular testing and ultrasound features will be used to predict if thyroid cancer is high risk. Intervention will be to perform more aggressive surgery to include total thyroidectomy with CCND.
Intervention Type
Procedure
Intervention Name(s)
Thyroid lobectomy
Intervention Description
Thyroid lobectomy is removal of only part of the thyroid
Intervention Type
Procedure
Intervention Name(s)
Total thyroidectomy with CCND
Intervention Description
Total thyroidectomy with central compartment lymph node dissection is removal of the entire thyroid with the surrounding lymph nodes
Primary Outcome Measure Information:
Title
Number of patients who require completion thyroidectomy for aggressive histology features
Description
Histology characteristics of tumor will be assessed including type of cancer, extrathyroidal extension, lymph node metastasis, and margin status to assess if completion thyroidectomy is needed per the 2015 ATA guidelines
Time Frame
2 years
Secondary Outcome Measure Information:
Title
Number of patients who had central compartment neck dissection but no lymph node metastasis were identified
Time Frame
2 years
Title
Number of patients with operative complications
Description
incidence of permanent nerve injury, hypocalcemia, readmission
Time Frame
2 years
Title
Recurrence
Time Frame
>2 years
Title
QOL metric - FACT-G cumulative score preop, postop, and at followup
Time Frame
2 years
Title
QOL metric - QOL-Thyroid cumulative score preop, postop, and at followup
Time Frame
2 years
Title
QOL metric - SF36 cumulative score preop, postop, and at followup
Time Frame
2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Thyroid nodule is >1.5 cm
Preoperative FNA biopsy that is positive for papillary thyroid cancer or suspicious for papillary thyroid cancer
Exclusion Criteria:
Prior thyroid/parathyroid surgery
Clinical indications for total thyroidectomy including hypothyroidism, history of head or neck radiation when <18 years old
Recurrent laryngeal nerve dysfunction
Diagnosis of concurrent primary hyperparathyroidism
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Linwah Yip, MD
Organizational Affiliation
University of Pittsburgh
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Pittsburgh
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
Medical College of Wisconsin
City
Milwaukee
State/Province
Wisconsin
ZIP/Postal Code
53226
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Molecular Testing to Direct Extent of Initial Thyroid Surgery
We'll reach out to this number within 24 hrs